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Abstract
Gastroesophageal reflux disease (GERD) is common, but less so than widely
reported because of inconsistencies in definition. In clinical practice, the
diagnosis is usually based on a symptom assessment without testing, and the
extent of diagnostic testing pursued should be limited to that which guides
management or which protects the patient from the risks of a potentially morbid
treatment or an undetected early (or imminent) esophageal adenocarcinoma or
which does both. When testing is pursued, upper gastrointestinal endoscopy is
the most useful initial diagnostic test because it evaluates for the major
potential morbidities (Barrett’s, stricture, and cancer) associated with GERD
and facilitates the identification of some alternative diagnostic possibilities such
as eosinophilic esophagitis. However, endoscopy is insensitive for diagnosing
GERD because most patients with GERD have non-erosive reflux disease, a
persistent diagnostic dilemma. Although many studies have tried to objectify
the diagnosis of GERD with improved technology, this is ultimately a pragmatic
diagnosis based on response to proton pump inhibitor (PPI) therapy, and, in the
end, response to PPI therapy becomes the major indication for continued PPI
therapy. Conversely, in the absence of objective criteria for GERD and the
absence of apparent clinical benefit, PPI therapy is not indicated and should be
discontinued. PPIs are well tolerated and safe, but nothing is perfectly safe, and
in the absence of measurable benefit, even a miniscule risk dominates the
risk-benefit assessment.
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Gastroesophageal reflux is a normal physiological event that 
commonly occurs during and after meals. However, gastroesopha-
geal reflux disease (GERD) is a “condition that develops when 
the reflux of stomach contents causes troublesome symptoms 
and/or complications”1. This umbrella definition was devised to 
encompass the broad spectrum of GERD, inclusive of endoscopi-
cally evident disease (esophagitis, stricture, Barrett’s metaplasia, 
and adenocarcinoma), troublesome esophageal symptoms without 
endoscopically evident disease (heartburn, regurgitation, and 
chest pain), and potential extra-esophageal manifestations such as 
laryngitis or cough.
Although the above definition of reflux disease, widely referred to 
as the Montreal definition, was intellectually satisfying in fusing 
the potential manifestations of GERD by the common element of 
stemming from the reflux of gastric content into the esophagus, it 
also posed some significant practical problems for the clinician. 
Notable among these are (1) how to establish causality between 
inherently non-specific symptoms and reflux and (2) defining the 
threshold frequency or severity at which a symptom becomes 
“problematic”. Grappling with these issues has fostered an envi-
ronment in which the over-diagnosis and over-treatment of GERD 
have become rampant. That, in turn, has led to the substantial 
overuse of GERD treatments, especially proton pump inhibitors 
(PPIs). It is from this background that we will address the follow-
ing emerging dilemmas of managing reflux in 2017: (1) How is 
GERD defined? (2) How is GERD diagnosed? And (3) what are 
the indications and risks for long-term PPI therapy?
How is gastroesophageal reflux disease defined?
The typical symptoms of GERD are heartburn (a burning 
sensation arising behind the breastbone toward the neck) and 
Figure 1. Symptom profiles of patients with and without objective evidence of gastroesophageal reflux disease (GERD) (upper 
gastrointestinal (GI) endoscopy or pH-metry or both) in the Diamond study2. The entry criterion for the multinational primary care study 
was the presence of a troublesome upper GI symptom. Plotted here were the dominant symptoms reported by each participant. All subjects 
were studied with endoscopy and pH-metry and underwent a structured interview with both a general practitioner and a gastroenterologist.
regurgitation (experienced as refluxed fluid moving in the chest 
or a bitter taste in the mouth). However, these typical symptoms 
are neither sensitive nor specific for GERD as demonstrated in the 
Diamond study2. In that study, 308 patients identified in primary 
care as having troublesome upper gastrointestinal (GI) symptoms 
underwent a comprehensive evaluation with endoscopy, esopha-
geal pH-metry, structured physician interviews, questionnaires, 
and a trial of PPIs, thereby allowing comparisons among these 
diagnostic methods. When endoscopy or pH-metry was used as 
the diagnostic standard, 203 (66%) of these patients had GERD, 
but as shown in Figure 1, only a minority of the patients with 
GERD had heartburn or regurgitation as their dominant symptom 
and more than a quarter of those without GERD indicated one 
of these as their dominant symptom. Not surprising then was the 
finding that the sensitivity and specificity of the Reflux Disease 
Questionnaire (RDQ) and the physician assessments were all in 
the range of 63% and 67%, respectively, against that same 
diagnostic standard.
The Diamond study also contrasted the diagnostic assignment 
made by endoscopy, pH-metry, and response to PPI therapy. 
Figure 2 illustrates the comparison between endoscopy and 
pH-metry. Note that only 20% of the patients with esophagitis 
had both abnormal esophageal acid exposure and a positive symp-
tom correlation during their wireless Bravo pH-metry study and 
that 34% had completely normal studies. Response to a 2-week 
trial of esomeprazole 40 mg did not clarify these discrepancies. 
Even though a beneficial PPI response, defined as absence of 
the dominant symptom for the final 3 days of the trial, was more 
frequent in patients with esophagitis (69%) and in patients with 
non-erosive reflux disease (NERD) (49%), 35% of patients with 
normal endoscopy and pH-metry also had a beneficial response3.
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Evidently, GERD is not so easily defined. The diagnosis is vari-
ably based on endoscopy, pH-metry, symptom assessment, or 
response to PPI therapy, but each of these modalities identifies a 
distinct patient population. Furthermore, although the severity of 
esophagitis correlates with the extent of esophageal acid exposure 
during pH-metry to some degree, the same relationship does not 
hold for reflux symptom severity. Clearly, the pathophysiologi-
cal determinants of reflux symptoms are somewhat distinct from 
those of mucosal erosion. Mucosal injury is facilitated by pro-
longed exposure to refluxed acid, pepsin, and bile acids. This is 
largely facilitated by an incompetent sphincter, hiatus hernia, 
and poor peristaltic function4,5. Symptoms, on the other hand, 
are strongly modulated by sensitivity. Only about 10% of reflux 
episodes are perceived6, and patients with GERD are more 
sensitive to esophageal stimuli than are control subjects7. Reflux 
episodes during which the refluxate reaches the proximal esopha-
gus (more common among patients with GERD) are also more 
likely to be symptomatic, and recent physiological data suggest 
that the proximal esophagus has distinct innervation compared 
with the distal esophagus8. Finally, the phenomena of hypersen-
sitivity and hypervigilance are increasingly recognized as major 
determinants of symptom perception and severity among subsets 
of patients with NERD9.
In regard to the opening question, there has been no standard-
ized way of defining GERD. Rather, investigators and clinicians 
have used definitions of convenience for the task at hand, be that 
research, a treatment trial, or a patient encounter. True, most such 
definitions will fit under the umbrella of the Montreal definition, but 
without further qualifications, the Montreal definition is too broad 
for most purposes. Furthermore, since the criteria used to define 
GERD in epidemiological studies (for example, self-reporting of 
at least weekly heartburn or regurgitation or both) are even more 
permissive than the Montreal definition, currently reported GERD 
prevalence rates ranging from 9% to 33%10 are likely to be over-
estimates.
How is gastroesophageal reflux disease diagnosed?
GERD is usually a clinical diagnosis based on a symptom assess-
ment. Testing is reserved for cases in which there are warning signs 
of complication (dysphagia, odynophagia, weight loss, bleeding, or 
anemia), atypical symptoms such that the diagnosis is uncertain, 
an inadequate response to medical treatment, or as a preoperative 
evaluation to confirm excessive reflux prior to surgical treatment. 
Hence, the management approach used varies greatly depending 
on a symptom assessment, an assessment of the risk that compli-
cations exist, the history and success of treatment trials, whether 
or not a potentially morbid therapy is under consideration, and the 
history of prior testing. As a general rule, the extent of diagnostic 
testing should be limited to that which guides management deci-
sions or which protects the patient from the risk of an inappropriate 
treatment or an undetected early (or imminent) cancer or which 
does both.
Symptom assessment and questionnaires
In clinical practice, the complaint of heartburn or acid regurgitation 
(or both) in a patient without signs of complications is sufficient 
to initiate anti-reflux therapy. Questionnaires have been devised to 
standardize the assessment of these symptoms in order to facilitate 
screening for GERD in primary care settings. Bolier et al. recently 
Figure 2. pH-metry findings among patients found to have reflux esophagitis on endoscopy in the Diamond study3. pH-metry was 
carried out by using the wireless Bravo system, and a single 24-hour period was analyzed. Studies were interpreted as positive or negative 
on the basis of both esophageal acid exposure (>5%) and a positive symptom association probability score for their dominant upper 
gastrointestinal (GI) symptom.
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reviewed 39 questionnaires to assess GERD symptoms, 14 to assess 
treatment response, and 18 to assess GERD-related quality of life11. 
Among these, the RDQ—consisting of six items that assess the fre-
quency and severity of heartburn, regurgitation, and dyspepsia—is 
one of the most widely used. The accuracy with which question-
naires diagnose GERD varies with what is used as the reference 
standard. If the comparison is with the diagnosis rendered by an 
experienced clinician, the correspondence is very good2; if the com-
parison is with pH-metry, endoscopy, or response to PPI therapy, 
the sensitivity and specificity are only about 65%12.
Upper gastrointestinal endoscopy
Upper GI endoscopy is the most useful diagnostic test in GERD 
management. Potential endoscopic findings that might direct 
management include reflux esophagitis, eosinophilic esophagitis, 
hiatus hernia, peptic ulcer, bleeding, stricture, Barrett’s esopha-
gus, and esophageal adenocarcinoma. With respect to diagnos-
ing esophagitis, the minimal endoscopic lesion with acceptable 
inter-observer agreement is a mucosal break, the basis for the Los 
Angeles classification. A mucosal break is defined as “an area of 
slough or erythema with a discrete line of demarcation from the 
adjacent, more normal looking mucosa”13. Within the Los Angeles 
scheme, the severity of esophagitis is graded A (minimal) through 
D (very severe) depending on the extent of the mucosal breaks 
observed13. However, NERD is the dominant form of GERD, and 
esophagitis will be absent in about 70% of cases being evaluated 
for reflux symptoms14. Consistent with this estimate, esophagi-
tis was reported in only 17.3% of 280,075 endoscopies in the 
Clinical Outcomes Research Initiative database and among these, 
79% were classed as mild and graded as Los Angeles A or B 
when Los Angeles grading was reported15. Attempts to extend the 
diagnostic sensitivity of endoscopy to microscopic lesions 
more subtle than mucosal breaks have applied techniques such 
as magnification endoscopy with a narrow band imaging light 
source16. However, within that context, it is important to note 
the finding of Los Angeles grade A esophagitis in 5% of asymp-
tomatic controls participating in a population-based endoscopy 
study17, leading some to question the significance of this (mac-
roscopic) finding. Similarly, histologic examination of mucosal 
biopsies might increase the sensitivity for detecting GERD, but 
again at the expense of specificity. Microscopic esophagitis (basal 
cell hyperplasia, papillary elongation, dilated intercellular spaces, 
and inflammation) was observed in 65% of patients with NERD 
but also in 15% of controls18,19. In summary, endoscopy is an 
important test to detect esophagitis, complications of GERD, and 
alternative diagnoses that might redirect therapy, but it has very 
poor sensitivity for diagnosing GERD.
Proton pump inhibitor trial
The unprecedented therapeutic efficacy of PPIs in healing 
esophagitis and resolving heartburn spawned the concept of 
using a short course of high-dose PPIs as a “diagnostic test” for 
GERD. However, responsiveness to PPIs, abnormal pH-metry, and 
symptom-based assessments each detect unique patient popula-
tions that only partially overlap; a positive (standard-dose) PPI 
response was observed in 69% of patients with and 51% of 
patients without endoscopic or pH-metry criteria (or both) for 
GERD in the Diamond study (Figure 3)3. Similarly, in a meta- 
analysis of 15 “PPI test” studies that used pH-metry as the 
reference standard, the positive likelihood ratio of the “PPI test” for 
predicting GERD was low, ranging from only 1.63 to 1.8720.
The imperfect overlap between patient populations defined by 
physiologic testing and response to a PPI trial does not negate the 
Figure 3. pH-metry findings versus response to a proton pump inhibitor (PPI) trial (esomeprazole 40 mg daily for 2 weeks) among all 
308 patients analyzed in the Diamond study2. pH-metry was carried out by using the wireless Bravo system, and a single 24-hour period 
was analyzed. Studies were interpreted as positive or negative on the basis of both esophageal acid exposure (>5%) and a positive symptom 
association probability score for their dominant upper gastrointestinal (GI) symptom. A positive response to the PPI test was defined as the 
absence of the dominant symptom for the last 3 of the 14 days.
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practicality and cost-effectiveness of empiric PPI therapy. Fass 
et al. calculated that, even though a “PPI test” had only 80% sen-
sitivity and 57% specificity for detecting physiologically defined 
GERD, this protocol saved an average of $348 per patient by 
reduction in the use of diagnostic testing21. Nonetheless, empiric 
PPI therapy has its limitations. A positive response may be 
attributable to a placebo effect or the presence of an alternative 
acid-peptic disorder, whereas a negative response may occur with 
symptoms refractory to PPI therapy4. Another important consid-
eration is the potential to foster unnecessary long-term PPI use, 
which has clinical and economic implications. In summary, 
empiric PPI therapy is a simple and cost-effective way to manage 
typical reflux symptoms in patients without warning signs, but the 
effectiveness of the therapy does not equate to a diagnosis of 
GERD or to a need for long-term PPI therapy.
Ambulatory gastroesophageal reflux disease testing: pH 
and pH-impedance monitoring
Ambulatory reflux monitoring can quantify reflux, potentially 
diagnosing GERD in patients without erosive reflux disease. 
Conventional (or wireless) pH-metry detects reflux events on the 
basis of their acidity, whereas pH-metry combined with imped-
ance detects all liquid or gas reflux events or both. Esophageal 
acid exposure is defined as the percentage of the recording 
time with esophageal pH of less than 4, and reported upper 
limits of normal range from 3.9% to 7.2%22–24. The reported 
sensitivity and specificity of pH-metry for differentiating 
control subjects from patients with esophagitis are 77–100% and 
85–100%, respectively25–28.
The yield of both pH-metry and pH-impedance monitoring 
can be increased by testing the relationship between reflux 
events and patient-reported symptoms, although in the case of 
pH-metry this analysis is restricted to acid reflux events. 
However, the significance of the increased yield of the symp-
tom-reflux relationship is unclear, given that only abnormal acid 
exposure has been shown to correlate with medical or surgical 
treatment outcome29. This is even more true in the case of pH- 
impedance testing where the added yield of detecting “non-
acid reflux” with impedance technology is negligible at best30. 
Similarly, except in unusual circumstances in which the pharma-
cological effectiveness of PPIs is in question, reflux monitoring 
studies should be done withholding PPI therapy for a week prior 
to (and during) the study to best address the question “Does my 
patient have pathological esophageal acid exposure?”31.
Risks and benefits of long-term proton pump 
inhibitor use
PPIs have revolutionized the medical approach to upper GI dis-
orders. Initially developed as a treatment for reflux esophagitis, 
these potent, well-tolerated inhibitors of gastric acid secretion 
have subsequently proven effective for a broad range of syndromes 
attributed to acid reflux, acid secretion, or acid hypersecretion. 
With these broadened indications came an exponential increase in 
worldwide PPI use32,33. Another offshoot of the success with PPIs in 
resolving reflux esophagitis has been the emergence of the logic in 
clinical practice that “if some is good, more is better” with respect 
to PPI dosage and symptom control, often ignoring the possibility 
that the syndrome in question had only a limited relationship to 
gastric acid secretion in the first place. This paradigm is especially 
relevant to suspected “atypical symptoms of GERD”; the obser-
vation that some cases of chronic laryngitis, cough, or wheezing 
improve with PPI therapy has led to the practice that all cases 
are being treated with high doses of PPIs for extended periods. 
Consequently, in less than 30 years, PPIs have evolved from 
tightly regulated medicines approved for short-term use in 
healing esophagitis to over-the-counter products advertised on 
television and billboards and used for a wide array of syndromes 
in which reflux may have a potentiating role. Not surprisingly, 
PPIs are often ineffective when used in this manner.
Coincident with surging PPI usage, the literature surrounding 
PPI safety and efficacy is also growing exponentially, making it 
difficult to differentiate fact from fiction. A recent effort at adding 
clarity to this issue was led by three Italian scientific societies in 
collaboration with an impressive collection of expert international 
reviewers. They performed a systematic literature review of almost 
500 papers and published a narrative review on the safety and 
appropriateness of PPI therapy34. Table 1 summarizes their key 
messages regarding appropriate long-term PPI use in GERD. 
Examining this result, one can’t help but reflect back to the 
Diamond study, specifically Figure 3. What this is suggesting is 
that—apart from the circumstances of high-grade esophagitis, 
eosinophilic esophagitis, or Barrett’s esophagus—long-term PPI 
use is warranted if it renders effective symptom control, regard-
less of any objective evidence of GERD. On the other hand, they 
suggest PPI use to be of uncertain benefit if the target symptoms 
were non-responsive or for “extra-digestive GERD”. Basically, this 
is advocating using the results of a PPI trial, for typical or atypical 
symptoms, to ascertain whether or not PPI therapy is appropriate.
Coupled with skyrocketing PPI usage has been unprecedented 
scrutiny of the safety of long-term use and a growing list of 
associated safety concerns. At and prior to approval, concerns 
related to chronic PPI therapy centered on consequences of 
pharmacologically induced hypochlorhydria: hypergastrinemia, 
gastric cancer, gastric carcinoid tumors, loss of gastric sterility, 
and micronutrient malabsorption. Hypergastrinemia and increased 
bacterial colonization of the stomach can be experimentally dem-
onstrated, but there have been no instances of gastric cancers, 
esophageal cancers, or carcinoids linked to chronic PPI therapy in 
Table 1. Summary of the conclusions by Scarpignato et al.34 
regarding the appropriateness of long-term PPI therapy in 
GERD.
Long-term PPI therapy appropriate PPI use of 
uncertain benefit
➢  Healing and maintenance of healed 
Los Angeles grade C or D erosive 
esophagitis
➢  PPI non-responsive 
GERD
➢  PPI-responsive GERD/non-erosive 
reflux disease
➢  Extra-digestive 
GERD
➢ Barrett’s esophagus
➢  PPI-responsive esophageal 
eosinophilia
GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor.
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Table 2. Potential adverse effects reported to be associated with PPI use stratified by estimate of causality along with 
proposed mechanism, risk estimate, and graded clinical significance.
Risks with an established causal relationship to PPI use
Putative risk Proposed mechanism Risk estimate/Evidence Clinical significance
Acute interstitial nephritis Idiosyncratic, rare Moderate (OR 5.16), 
Observational (case-control)
Emphasizes need for valid 
PPI indication
Fundic gland polyp Hypergastrinemia Low (OR 2.45), Systematic 
review, meta-analysis
Minimal
Hypomagnesemia (severe) Idiosyncratic, rare Unable to calculate, 
Observational (case reports)
Emphasizes need for valid 
PPI indication
Iron deficiency Hypochlorhydria, poor 
absorption
Low (OR 2.49), Observational 
(case-control)
Minimal; treatable and 
reversible
SIBO Hypochlorhydria, loss of 
gastric sterility
Low (OR 2.28), Meta-analysis Minimal; treatable and 
reversible
Vitamin B12 deficiency Hypochlorhydria, poor 
absorption
Low (HR 1.83) Systematic 
review, meta-analysis
Minimal; treatable and 
reversible
Risks with a weak association with PPI use
Bone fracture Hypochlorhydria, poor 
calcium absorption
Low (OR 2.65), Observational 
(case-control)
Minimal; standard bone 
health recommendations
Chronic kidney disease Not established Low (HR 1.50), Observational 
(population-based cohort)
Minimal; evidence is too 
weak
Clostridium difficile–associated 
diarrhea
Hypochlorhydria, loss of 
gastric sterility
Low (RR 1.69), Meta-analysis Minimal; emphasizes need 
for valid PPI indication
Dementia Beta-amyloid deposits Very low (HR 1.44), Observational 
(prospective cohort)
Minimal; evidence is too 
weak
Hepatic encephalopathy in 
patients with cirrhosis
SIBO, bacterial translocation Low (HR 1.72), Observational 
(case-control)
Minimal; emphasizes need 
for valid PPI indication
Spontaneous bacterial peritonitis 
in patients with cirrhosis 
SIBO, bacterial translocation Low (OR 2.28), Systematic 
review, meta-analysis
Minimal; emphasizes need 
for valid PPI indication
Hypothesized risks of PPI use, but not reported or observed
Community-acquired 
pneumonia
Loss of acid-mediated gastric 
sterility, aspiration
Very low (OR 1.49), Systematic 
review, meta-analysis
Minimal; evidence is too 
weak
Acute cardiovascular events Drug-drug interaction with 
hepatic metabolism of 
clopidogrel
Not observed (HR 0.99), 
Randomized controlled trial
Minimal; evidence does not 
support
HR, hazard ratio; OR, odds ratio; PPI, proton pump inhibitor; RR, relative risk; SIBO, small intestinal bacterial overgrowth.
humans35. On the other hand, gastric acid does facilitate iron and 
vitamin B12 absorption and long-term PPI use has a dose-dependent 
effect on clinical iron and B12 deficiency36,37. Hypochlorhydria also 
interferes with the stomach’s bactericidal function, and long-term 
users are more prone to enteric infections, including Clostridium 
difficile (up to three-fold increase), Campylobacter, Salmonella 
(two- to six-fold increase), and small intestinal bacterial over-
growth (two- to eight-fold increase)38. Conversely, despite intense 
scrutiny for more than ten years, evidence does not support 
clinically relevant calcium malabsorption or an increased risk of 
community-acquired pneumonia with chronic PPI use38.
Mass population exposure to PPIs has also revealed potential 
idiosyncratic reactions. An observational case-control study 
reported a five-fold increased risk of acute interstitial nephritis 
among PPI users39. Rare isolated cases of profound PPI-associ-
ated hypomagnesemia have also been reported40. However, in 
neither case is the mechanism understood, and attempts at linking 
PPI use with chronic kidney disease or hypomagnesemia in pop-
ulation-based studies have yielded only very low hazard ratios 
(≤1.5), likely representing noise rather than signal40. Similar weak 
associations with PPI use have been reported for dementia and 
myocardial infarction in population-based epidemiology studies 
or meta-analyses or both38,41. However, in the case of myocardial 
infarction, this was also tested in a randomized controlled trial. 
The Clopidogrel and the Optimization of Gastrointestinal Events 
Trial (COGENT) randomly assigned patients with an indication 
for dual anti-platelet therapy to receive clopidogrel and aspirin 
in combination with either omeprazole or placebo. Not only did 
the omeprazole group experience significant benefit with respect 
to reduced GI bleeding (P <0.001) but cardiovascular events 
were actually marginally less frequent, occurring in 4.9% of the 
omeprazole group compared with 5.7% in the placebo group (not 
significant)42. Clearly, observational studies have their limits; 
these studies are inherently flawed by an inability to establish 
causality, unmeasured confounders, inaccurately measured con-
founders, and unaccounted-for biases43. Hence, findings of weak 
associations should be viewed as hypothesis-generating rather 
than a cause for public hysteria.
Table 2 summarizes available safety information on long-term PPI 
use with the concerns grouped by the strength of substantiating 
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data and coupled with risk estimate, proposed mechanism, and 
significance. In the table, there is little of sufficient concern to 
alter practice, provided that PPI use is appropriate.
Conclusions
GERD is common but being more exact than that is difficult 
because of inconsistencies in how GERD is defined. In clinical 
practice, the diagnosis is commonly based on a symptom assess-
ment without testing, and, as a general rule, the extent of diag-
nostic testing should be limited to tests which guide management 
decisions, detect alternate diagnoses and/or protect the patient 
from the risk of an inappropriate treatment. The management 
approach used varies depending on an assessment of the risk that 
complications exist, the history and success of treatment trials, 
whether or not a potentially morbid therapy such as anti-reflux 
surgery is under consideration, and the history of prior testing. 
When testing is pursued, upper GI endoscopy is the most useful 
initial diagnostic test because it evaluates for the major poten-
tial morbidities (Barrett’s, stricture, and cancer) associated with 
GERD and allows for the exclusion of some alternative diagnos-
tic possibilities. However, endoscopy is insensitive for diagnosing 
GERD because most patients with GERD have NERD, which 
remains a diagnostic dilemma. Although many studies have tried 
to objectify the diagnosis of GERD with improved technology, 
this is ultimately a pragmatic diagnosis based on response to PPI 
therapy, and, in the end, response to PPI therapy becomes the 
major indication for continued PPI therapy. Conversely, in the 
absence of objective criteria for GERD and of apparent clinical 
benefit, PPI therapy is not indicated and should be discontinued. 
PPIs are well tolerated and safe, but nothing is perfectly safe, and 
in the absence of measurable clinical benefit, even a miniscule risk 
dominates the risk-benefit assessment.
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